Posted this back in February 2017: Voyager is e
Post# of 30028
(Total Views: 791)
Posted On: 09/06/2017 4:40:08 PM
Posted this back in February 2017:
Voyager is exclusively dedicated to advancing gene therapy trials in the CNS space. And they are sitting on $191M in cash.
There are three approaches to gene therapy in Parkinson's. See below.
http://pdcenter.neurology.ucsf.edu/profession...therapy-pd
Voyager is advancing approach #1 using the gene for the enzyme aromatic amino acid decarboxylase (AADC).
Amarantus and MANF targets approach #3 - using brain proteins called 'growth factors' such as MANF that may protect against progression of Parkinson's disease or possibly even reverse it by stimulating regrowth of injured nerve cells. Both MANF and CDNF appear more promising than the first growth factor studied - GDNF - in this regard.
AMBS could be sitting on a momentous scientific breakthrough here, but first the company needs to get back on its feet financially. I hope this happens sooner rather than later because the scientific evidence behind MANF in both Parkinson's and eye disorders continues to mount with every passing day.
Read More: https://investorshangout.com/post/view?id=433...z4rvveYbrD
Voyager is exclusively dedicated to advancing gene therapy trials in the CNS space. And they are sitting on $191M in cash.
There are three approaches to gene therapy in Parkinson's. See below.
http://pdcenter.neurology.ucsf.edu/profession...therapy-pd
Voyager is advancing approach #1 using the gene for the enzyme aromatic amino acid decarboxylase (AADC).
Amarantus and MANF targets approach #3 - using brain proteins called 'growth factors' such as MANF that may protect against progression of Parkinson's disease or possibly even reverse it by stimulating regrowth of injured nerve cells. Both MANF and CDNF appear more promising than the first growth factor studied - GDNF - in this regard.
AMBS could be sitting on a momentous scientific breakthrough here, but first the company needs to get back on its feet financially. I hope this happens sooner rather than later because the scientific evidence behind MANF in both Parkinson's and eye disorders continues to mount with every passing day.
Read More: https://investorshangout.com/post/view?id=433...z4rvveYbrD
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼